重庆大学附属三峡医院特聘教授，博士生导师

联系方式：yinmingzhu2008@126.com

教育经历：

2018年，耶鲁大学&中国药科大学联合培养 中西医结合专业（博士）；

2011年，哈尔滨医科大学 肿瘤学专业（硕士）；

2008年，哈尔滨医科大学  临床医学专业（本科）；

工作经历：

2023-至今，重庆大学附属三峡医院特聘教授，博士生导师，肿瘤早期诊断中心、临床病理中心及临床研究中心主任；拟任重庆大学转化医学中心主任；

2020-至今，美国耶鲁大学医开云平台(中国)有限公司，病理科，兼职助理教授；

2018-2022，中南大学湘雅医院，皮肤科副主任、皮肤健康与疾病湖南省工程研究中心常务副主任，特聘教授；博士生导师；

2017-2018年，美国耶鲁大学医开云平台(中国)有限公司，病理科，副研究员；

2013-2016年，美国耶鲁大学医开云平台(中国)有限公司，病理科，博士后；

2012年，美国国立卫生研究院抗衰老研究所（NIH/NIA）遗传系博士后；

2011年，哈尔滨医科大学附属肿瘤医院，主治医师。

获社会兼职：

旅美科技协会副会长，重庆市联络站负责人；

中美药学协会康州分会常务理事；

中国微循环学会转化医学专委会常委，青年副主任委员；

湖南省口腔医学会首届口腔-头颈肿瘤MDT专业委员会常委

中国医师协会皮肤科医师分会罕见&遗传性皮肤病分会委员。

Tumor Discovery杂志创刊主编

Cancer Translation Medicine杂志副主编

Frontiers in Immunology 和Frontiers in Oncology客座主编

获得荣誉：

发明专利：

1. 专利名称：宫颈癌患者使用紫杉醇和顺铂进行化疗敏感性预测方法.

发明人：侯艳，印明柱，孙风宇，娄阁，李康 申请号：201510164414.2

2. 专利名称：杂环化合物及其盐、制备方法、用途和药物.发明人：印明柱，陈翔 专利号：ZL2018 1 1204859.9 授权号：CN109134448 B

3. 专利名称：荧光酶抑制剂筛选模型建立方法及荧光酶抑制剂筛选方法. 发明人：印明柱、曹东升、杨梓宜、陈翔. 申请号：202010715628.5

4. 专利名称：分子靶标蛋白的筛选方法、装置、计算机设备和存储介质. 发明人：印明柱、曹东升、杨素青、陈翔. 申请号：202010716290.5

5. 专利名称：胶体筛选模型的构建方法和胶体筛选方法. 发明人：曹东升、印明柱、陈翔、杨梓宜. 申请号：202010818121.2

6. 专利名称：药物与靶点间的相互作用关系预测方法及装置. 发明人：曹东升、印明柱、陈翔、杨素青、程岩. 申请号：202010824226.9

7. 专利名称：诱导肝毒性预测方法、装置、计算机设备及存储介质. 发明人：曹东升、印明柱、陈翔、付丽、刘璐. 申请号：202010835987.4

8. 专利名称：药物副作用关系预测方法、系统、计算机设备和存储介质. 发明人：曹东升、印明柱、陈翔、杨素青. 申请号：202010837504.4

9. 专利名称：细胞分类方法、装置、计算机设备和存储介质.发明人：印明柱、李轶群、陈翔. 申请号：202010840988.8

10. 专利名称：原代肢端黑色素瘤细胞的培养方法及培养试剂盒. 发明人：印明柱、胡睿、陈翔. 申请号：202010705199.3

11. PCT专利名称：CD147-ANTIBODIES AND ANTI-CD147-CAR-T CELLS.发明人：陈翔、印明柱申请号：119995-8033.US00

12. 专利名称：一种人细胞外基质金属蛋白酶诱导因子磁微粒化学发光免疫定量检测试剂盒及其检测方法.印明柱、陈翔. 申请号：202210207499.8

13. 专利名称：5-硫-D-葡萄糖的合成方法.廖潇啸、印明柱、陈翔. 申请号：202210336519.1

14. 专利名称：一种同时识别多种恶性肿瘤细胞的核酸适体及其应用. 蒲颖、印明柱、陈翔. 申请号：CN114507668A

课题基金：

序号	项目名称	主持/承担	立项编号	经费(万元)	起止年月	性质及来源
1	BRD4及其抑制剂调控HIPPO/YAP1通路防治黑素瘤增殖、侵袭及转移机制研究	主持	82073020	55	2021/01-2024/12	国家自然科学基金面上项目
2	基于BRD4通过c-MYC-MYH9轴调控MYH9与HIF-1α相互作用探讨BET抑制剂防治黑素瘤转移的机制研究	主持	81874138	57	2019/01-2022/12	国家自然科学基金面上项目
3	老年常见皮肤病防控及干预关键技术创新及应用	子课题负责人	2022YFC3601802	388.77	2023/01-2028/12	科技部重点研发项目：
4	皮肤疾病药理学	81202282	2021JJ10073	50	2021/01-2023/12	湖南省杰出青年基金

成果转化:

新药等级	成果简介	本人作用和主要经济社会效益
1.1靶向新药新药	BET抑制剂以BRD2/3/4为靶标，主要通过其溴化结构域蛋白（BET）特异性地识别乙酰化赖氨酸的保守蛋白结构域，在转录蛋白表达中通过参与蛋白-蛋白的相互作用，促进蛋白复合物形成并提高部分基因的转录功能。临床试验观察显示：BET抑制剂对血液肿瘤治疗表现尚好，但是对实体瘤治疗有相当大的局限性，成为本领域的技术瓶颈。现阶段团队已开发的具有独立知识产权的1.1类新药BET抑制剂NHWD-870，具有高效及高特异性特点，该项目已获批国家药监局临床试验批件2项，正在进行临床Ⅰ期试验。	申请人作为本项目主要负责人，负责该项目整体管理及统筹，其具体为临床前实体筛选、药效评价、毒理评估及临床试验批件申报等。 申请人自主研发新型BET抑制剂NHWD-870主要临床适应症为难治性复发的晚期癌症病人，这部分患者在临床上已经无药可用，研发此药物有望成为这部分患者最后医治的希望，具有重大临床应用价值和现实的社会效益。

讲授课程：

序号	课程名称	学期数	总学时数	选学总人数
1	生物技术技能培训（耶鲁大学医开云平台(中国)有限公司）	2	48	34
2	组织病理实验技术培训（耶鲁大学医开云平台(中国)有限公司）	4	96	15
3	皮肤病基础与临床研究设计	1	8	45

著作：

论文、著作名称	年份	排名	发表刊物名称	本人作用和主要贡献
教辅《轻松学习病理学》	2018	主编	湖北科学技术出版社 （ISBN：978-7-5352-9643-6）	负责本书整体的设计、排版、校对等工作，同时负责第7章节的撰写工作
教辅《临床病理生理学》	2022	主编	湖北科学技术出版社 （ISBN：978-7-5706-2212-2）	负责本书整体的设计、排版、校对等工作，同时负责10，18和20章节的撰写工作
专著《肿瘤标志物》	2022	编委	人民卫生出版社 （ISBN：9787117330817）	负责第3章-单细胞技术进展内容的编写工作
教材《临床研究伦理学》	未出版	编委	人民卫生出版社（书号：未出）	负责第5章-临床研究中人类遗传资源管理内容的编写工作

发表文章：

（共发表SCI论文83篇，第一/通讯（含共同）37篇,Google学术H指数30）

2010 (2)

1. Meng FL,^#Mingzhu Yin, Song HT, Yang H, Lou G, Zhou RL.LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.Int J Gynecol Cancer. 2010; 20(5):745-50.

2. Meng F,^#Luo C, Hu Y, Mingzhu Yin, Lin M, Lou G, Zhou R. Overexpression of   LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.Int J Gynecol Pathol. 2010; 29(6):587-93.

2011 (4,3)

3. (1) Mingzhu Yin,^# Ye Xu, Ge Lou, Yan Hou, Fanling Meng, Haiyu Zhang, Cong Li and Rouli Zhou. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis.Int J Cancer. 2011.129(3):629-35.

4. (2) Mingzhu Yin,^#Falin Zhao, Ge Lou, Haiyu Zhang, Meng Sun, Cong Li , Yan Hou, Xia Li, Fanling Meng and Xiuwei Chen. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced stage cervical cancer.Int J Gynecol Cancer.2011;21(1):92-99.

5. (3) Mingzhu Yin,^#Cong Li,^#Xia Li, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.J Surg Oncol, 2011,104(1):29-36.

6. Meng F, Song H, Luo C, Mingzhu Yin, Ye Xu, Haixia Liu, Rouli Zhou, Ge Lou.  Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 2011,117(12):252-8.

2012 (5,3)

7. (4) Mingzhu Yin,^#Haiyu Zhang, GeLou, et al.The toxicity and long-term efficacy of nedaplatin and  paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol,2012;105(2):206-11.

8. (5) Mingzhu Yin,^#Chong Lou, Wang Zhang, Fanling Meng, Haiyu Zhang,   Xiaoming Ning, Rouli Zhou, Xinshu Dong, Ge Lou. LAPTM4B over-expression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer, 2012;22(1):54-62.

9. Zhang T, Wu X,Mingzhu Yin, et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.Clin Chim Acta. 2012;413(9-10):861-8.

10. Fan L, Zhang W, Mingzhu Yin, et al.Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.Acta Oncol. 2012;51(4):473-9.

11. Kang Y, Mingzhu Yin, Jiang W,et al.  Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.Am J Surg. 2012; 204(5):667-83.

2013 (2)

12. Tao Zhang, Xiaoyan Wu, Chaofu Ke, Mingzhu Yin, Zhenzi Li, Lijun Fan, Wang Zhang, Haiyu Zhang, Falin Zhao, Xiaohua Zhou, Ge Lou and Kang Li.Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling.J Proteome Res. 2013; 12(1):505-12.

13. (6) Mingzhu Yin,^#Yan Hou,^#Tao Zhang, Changyi Cui, Xiaohua Zhou, Fengyu Sun, Huiyan Li, Xia Li, Yunduo Liu, Xiaoming Ning, Kang Li, Ge Lou. Evaluation of Chemotherapy Response with Serum Squamous Cell Carcinoma Antigen Level in Cervical Cancer Patients: A Prospective Cohort Study. Plose one. 2013; 8(1): e54969.

2014 (3,1)

14. Chang-yi Cui,^#Mingzhu Yin,Jian Sima, Victoria Childress, Marc Michel, Yulan Piao, David Schlessinger. Involvement of Wnt, Eda and Shh at defined stages of sweat gland development.Development. 2014; 141(19):3752-60.

15. (7) Yan Hou,^#Mingzhu Yin,^#Fengyu Sun, et al.Metabolomics Approach for Predicting Response to Neoadjuvant Chemotherapy in Cervical Cancer Patients.Molecular biosystems; 2014. 10(8):2126-33. (Contributed equally)

16. Tingting Ge,^#Mingzhu Yin, Mei Yang, et al.MicroRNA-302b Suppresses Human Epithelial Ovarian Cancer Cell Growth by Targeting RUNX1. Cell Physiol Biochem.2014, 34:2209-20.

2015 (3,3)

17. (8)Yuguang Ye,^#Mingzhu Yin,^#Bihui Huang et al. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.Tumor Biology. 2015, 36(6):4175-9.(Contributed equally)

18. (9)WeidongJi,^#YonghaoLi,^#YunHe,^#MingzhuYin,^#HuanjiaoZhou, Boggon TJ, HaifengZhang, WangMin. AIP1 expression in tumor niche suppresses tumor progression and metastasis. Cancer Research.2015. 75(17):3492-504 (Contributed equally)

19. (10) Mingzhu Yin,^# Shu Tan,^# Xia Li, et al. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. Tumour Biol.2015, 37(4):5485-92.

2016 (7,2)

20. Chang-Yi Cui, Jian Sima, Mingzhu Yin, Marc Michel, Makoto Kunisada, DavidSchlessinger. Identification of potassium and chloride channels in eccrine sweat glands. J DermatologicalScience. 2016; 81(2):129-31.

21.Guosheng Cao, Xinyi Ye, Yingqiong Xu, Mingzhu Yin,et al. Yiqifumai Powder Injection ameliorates blood-brain barrier dysfunction and brain edema after focal cerebral ischemia-reperfusion injury in mice. Drug Design, Development and Therapy, 2016; 10:315-25.

22. (11) Mingzhu Yin,^#Bihui Huang,^#Xia Li, Guosheng Cao, Jin Qi, Ge Lou, Shijie Sheng, Junping Kou, Kang Chen, Boyang Yu, Migration-Inducing Protein 7 Promotes Tumorigenesis and Angiogenesis and Independently Predicts Poor Prognosis of Epithelial Ovarian Cancer. Oncotarget, 2016, 7(19):27552-66.

23.Lijun Fan, Mingzhu Yin, Ke C, Ge T, Zhang G, Zhang W, Zhou X, Lou G, Li K. Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer.J Cancer2016; 7(10):1265-72.

24.Siying Zou, Alexandra M. Teixeira, Mingzhu Yin, Yaozu Xiang, PingXia Zhang, John Hwa, Wang Min, and Diane S. Krause. Leukemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thrombosis and Haemostasis2016; 116(3): 506-16. (Cover story).

25.Cao G, Jiang N, Hu Y, Zhang Y, Wang G, Yin M, et al. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway.Int J Mol Sci. 2016; 17(9). pii: E1418.

26. (12) Mingzhu Yin,^#  Xia Li,^#  Shu Tan,^#Huanjiao (Jenny) Zhou, Weidong Ji, Stefania Bellone, Xiaocao Xu, Haifeng Zhang, Alessandro D Santin, Ge Lou, Min, Wang.Tumor-Associated Macrophages Drive Spheroid Formation During Early Transcoelomic Metastasis of Epithelial Ovarian Cancer.J Clinical Investigation2016; 126(11):4157-4173. (Cover Story). Mingzhu Yin,^#et al. Macrophages activates ovarian cancer tumor cell proliferation and migration during metastasis. Videosfor J Clinical Investigation 2016 (Accepted). (IF:19.456，JCR 1区)

2017 (5,3)

27.(13) Linlin Li, Xiaoyong Wei, Baofeng Wu, Yuanli Xiao, Mingzhu Yin^#and Qiaohong Yang^#. siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. Oncology letters, 2017;13(5):3014-3024. (IF:3.111，JCR 4区)

28. (14) Liangyu Zhang, Zelong Fu, MD, Xia Li, Haitao Tang, Jiesi Luo, Dehui Zhang, Yongzhi Zhang, Zhiyang Han^#andMingzhu Yin^#. TAK1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway.Chemical Biology & Drug Design, 2017; 90(3):450-455. (IF:2.84，JCR 4区)

29.Yang K, Xia B, Wang W, Cheng J, MingzhuYin, et al. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Sci Rep.2017; 7:43353.

30.Shu Tan, Feng B, Mingzhu Yin, et al. Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression. Cell Biosci.2017; 7:36.

31. (15) Mingzhu Yin,Huanjiao Jenny Zhou, Jiqin Zhang, et al. ASK1-dependent endothelial cell activation play a critical role in ovarian cancer growth and metastasis. JCI Insight. 20172(18): e91828. (IF:9.484，JCR 1区)

2018 (2)

32.Li J, Yin M, Song W, Cui F, Wang W, Wang S, Zhu H. B Subunit of Human Chorionic Gonadotropin Promotes Tumor Invasion and Predicts Poor Prognosis of Early-Stage Colorectal Cancer.Cell Physiol Biochem. 2018; 45(1):237-249.

33. Long L, Yin M, Min W. 3D Co-culture System of Tumor-associated Macrophages and Ovarian Cancer Cells.Bio Protoc. 2018, 20;8(8). 8(8). pii: e2815.

34. Han Z，Hu H，Yin M，Li X，Li J，Liu L，Liu B*. miR-145 is critical for modulation of vascular smooth muscle cell proliferation in human carotidartery stenosis Journal of Biological Regulators and Homeostatic Agents. 2018, 32(3); pp 507-516.

2019 (2,2)

35. (16)Hu B, Hu H, Yin M*, Sun Z, Chen X, Li Y, Sun Z, Liu C, Li L, Qiu Y*. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain.Int J Cancer. 2019;144(3):558-568. (IF:7.4，JCR 1区)

36. (17) Yin M, Zhou HJ, Lin C, Long L, Yang X, Zhang H, Taylor H, Min W*. CD34+ KLF4+ Stromal Stem Cells Contribute to Endometrial Regeneration and Repair. Cell Rep. 2019; 27(9):2709-2724.e3. (IF:10，JCR 1区)

2020 (20,7)

37. Hu R, Han C, Pei S, Yin M*, Chen X*. Procalcitonin Levels in COVID-19 Patients. Int J Antimicrob Agents. 2020;1 56(2):106051.(IF:15.44，JCR 1区) 高被引

38. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020: S0923-1811(20)30197-3.

39. Yin M*, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X, Yan Q. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020;11(1):1833. (IF:17.69，JCR 1区). F1000论文

40. Liu N, Qi M, Li K, Zeng W, Li J, Yin M, Liu H, Chen X, Zhang J, Peng C. CD147 Regulates Melanoma Metastasis via the NFAT1-MMP-9 Pathway. Pigment Cell Melanoma Res. 2020 33(5):731-743.

 41. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of Inflammatory Markers with the Severity of COVID-19: A Meta-Analysis. Int J Infect Dis. 2020; 96:467-474.

 42. Deng G, Zeng F*, Zhang L*, Chen H*, Chen X*,Yin M*. Characteristics of Pregnant COVID-19 Patients with Liver Injury. J Hepatol. 2020; S0168-8278(20)30395-0. (IF:30.08，JCR 1区)

 43.Li Z, Yin M^#, Zhang H, Ni W, Pierce RW, Zhou HJ, Min W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circ Res. 2020;126(4):471-485.(IF:23.21，JCR 1区)

 44. Xue Y, Liu Y, Bian X, Zhang Y, Li Y*, Zhang Q*, Yin M*. miR-205-5p Inhibits Psoriasis-Associated Proliferation and Angiogenesis: Wnt/β-catenin and Mitogen-Activated Protein Kinase Signaling Pathway Are Involved. J Dermatol.2020;47(8):882-892.(IF:4.01，JCR 1区)

 45. Chen XS, Wang KS, Guo W, Li LY, Yu P, Sun XY, Wang HY, Guan YD, Tao YG, Ding BN, Yin M, Ren XC, Zhang Y, Chen CS, Ye YC, Yang JM, Cheng Y. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics. 2020;10(4):1833-1848.

 46. Pei S, Xue Y, Zhao S, Alexander N, Mohamad G, Chen X*, Yin M*. Occupational Skin Conditions on the Front Line: A Survey Among 484 Chinese Healthcare Professionals Caring for Covid-19 Patients. J Eur Acad Dermatol Venereol. 2020;10. 34(8):e354-e357. (IF:9.228，JCR 1区)

 47. Li LY, Chen XS, Wang KS, Guan YD, Ren XC, Cao DS, Sun XY, Li AX, Tao YG, Zhang Y, Yin MZ, Wang XL, Wu MH, Yang JM, Cheng Y. RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. Oncogene. 2020. 39(43):6704-6718.

 48. Liao M, Zeng F, Li Y, Gao Q, Yin M, Deng G, Chen X. A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients.Sci Rep. 2020;10(1):12462.

 49. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Association of Socioeconomic Changes due to the COVID-19 Pandemic With Health Outcomes in Patients With Skin Diseases: Cross-Sectional Survey Study. J Med Internet Res. 2020;22(9):e22288.

 50. Deng G^#, Zeng F^#, Su J, Zhao S, Hu R, Zhu W, Hu S, Chen X*, Yin M*. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020;10(25):11428-11443.(IF:11.6，JCR 1区)

51. Guan Y, Jiang S, Ye W, Ren X, Wang X, Zhang Y, Yin M, Wang K, Tao Y, Yang J, Cao D, Cheng Y. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy. Cell Death Dis. 2020;11(11):948.

52. Yang SQ, Ye Q, Ding JJ, Yin MZ, Lu AP, Chen X, Hou TJ, Cao DS. Current advances in ligand-based target prediction. WIREs Comput Mol Sci. 2020 (online).

53. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases.J Dermatol Sci. 2020;99(3):146-151.

54. Deng G,Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19.Crit Care. 2020;24(1):179.

55. Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, Kuang Y. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020;21(1):999.

56. Panchaud A, Favre G, Pomar L, Vouga M, Aebi-Popp K, Baud D; COVI-Preg group (Mingzhu Yin). An international registry for emergent pathogens and pregnancy.Lancet. 2020;395(10235):1483-1484.

2021 (14,3)

57. Shiyao Pei^#, Xi Yuan^#, Zhimin Zhang^#, Run Yao , Yubin Xie, Minxue Shen, Bijuan Li* , Xiang Chen*, Mingzhu Yin*. Convalescent Plasma to Treat COVID-19: Clinical Experience and Efficacy. Aging (Albany NY). 2021;13 (6), 7758. (IF:5.955, JCR 1区)

58. Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021; 503:240-248.

59. Vouga M, Favre G, Martinez-Perez O,----- Yin M, Haessig A, Ackermann S, Baud D, Panchaud A. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11(1):13898.

60. Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, Luo Y, Kuang YH, Zhu W. Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Front Med (Lausanne). 2021; 7:560579.

  61. Dong L^#, Pei S^#, Ren Q, Fu S, Yu L, Chen H, Chen X*, Yin M*. Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns. Placenta. 2021;111:91-96. (IF:3.481)

  62. Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. QSAR-assisted-MMPA to expand chemical transformation space for lead optimization. Brief Bioinform. 2021; bbaa374.

  63. Yang ZY, Dong J, Yang ZJ, Yin M, Jiang HL, Lu AP, Chen X, Hou TJ, Cao DS. ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds.Brief Bioinform. 2021;22(4): bbaa282.

64. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Unemployment and Health-Related Quality of Life in Melanoma Patients During the COVID-19 Pandemic.Front Public Health. 2021; 9:630620.

65. Yang ZY, Yang ZJ, Zhao Y, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. PySmash: Python package and individual executable program for representative substructure generation and application.Brief Bioinform. 2021: bbab017.

66. Hu R, Zhao S, Su J, Chen X*, Yin M*. Establishment of cultured primary acral melanoma cells and animal models for Chinese patients.Pigment Cell Melanoma Res. 2021.34 (6), 1131-1137. (IF:4.693)

 67. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties.Nucleic Acids Res. 2021;49(W1):W5-W14.

67. Jiang Y, Wang G, Mu H, Ma X, Wang Z, Lv Y, Zhang T, Xu J, Wang J, Li Y, Han J, Yang M, Wang Z, Zeng K, Jin X, Xue S, Yin M, Sun W, Hua Y, Cai Z. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling.Front Oncol. 2021;11:642134.

68. Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, Yan B, Guo Y, Zhou J, Tao J, Hu S, Chen X, Peng C. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.Mol Ther. 2021;29(7):2321-2334.

69. Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.Genome Med. 2020;12(1):83.

70.   Zhang SM,  Cai WL,  Liu X,  Thakral D,  Luo J,  Chan LH,  McGeary MK,  Song E,  Blenman KRM,  Micevic G,  Jessel S,  Zhang Y,  Yin M,  Booth  CJ,  Jilaveanu LB,  Damsky W,  Sznol M,  Kluger HM,  Iwasaki A,  Bosen           berg MW,  Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.Nature 2021,598 (7882), 682-687.

2022 (14,8)

71. Meiling Zhang, Zongzhi Z Liu, Keisuke Aoshima, Wesley L Cai, Hongyin Sun, Tianrui Xu, Yangyi Zhang, Yongyan An, Jocelyn F Chen, Lok Hei Chan, Asako Aoshima, Sabine M Lang, Zhenwei Tang, Xuanlin Che, Yao Li, Sara J Rutter, Veerle Bossuyt, Xiang Chen, Jon S Morrow, Lajos Pusztai, David L Rimm, Yin M*, Qin Yan*.  CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses. Science Translational Medicine. 2022, 14 (630), eabf5473. (IF:19.319) F1000论文.

72. Songtao Du^#, Furong Zeng^#, Huiyan Sun, Yanlong Liu, Peng Han, Bomiao Zhang, Weinan Xue, Guangtong Deng*, Yin M*, Binbin Cui*. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. Bioengineered. 2022, 13 (2), 2498-2512. (IF:6.832)

73. Deng G, Zeng F, He Y, Meng Y, Sun H, Su J, Zhao S, Cheng Y, Chen X*, Yin M*. eEF2K silencing inhibits tumor progression through repressing SPP1 and synergizes with BET inhibitors in melanoma. Clinical and Translational Medicine. 2022;12(2):e722. (IF:15.831)

74. Hongyin Sun, Bihui Huang, Jian Cao, Qin Yan and Mingzhu Yin*. Editorial: Epigenetic Regulation and Tumor Immunotherapy. Frontiers in Oncology. 2022, 12:893157. (IF:6.244)

75. Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M*, Cheng Y*. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022;10(3):e004026. (IF:12.469)

76. Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, Zhang X, Su J, Zhao S, Liu H, Yin M, Wu D, Wan M, Xie L, Chen X. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Br J Dermatol. 2022 Apr 19. doi: 10.1111/bjd.20976.

77. Jiang R, Xu J, Zhang Y, Liu J, Wang Y, Chen M*, Chen X*, Yin M*.
Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomed Pharmacother. 2022;150:113010. (IF:7.419)

78. Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, Su J, Yin M, Sznol M, Ariyan S, Clune J, Olino K, Parida L, Nikolaus J, Zhang M, Zhao S, Wang Y, Huang G, Wan M, Li X, Cao J, Yan Q, Chen X, Newman AM, Halaban R. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.Nat Commun. 2022;13(1):898.

79. Fu X , Yin M*. Monocytes in tumor: from the sight of Single-cell analysis. 2022, Tumor Discovery 1 (1), 1-19.

80. Yin M. Editor’s foreword to the inaugural issue of Tumor Discovery. Tumor Discovery 1 (1), 1-3.

81. Xu Zhang--Yin M, et al. CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. J Exp Clin Cancer Re, 2022;41(1):246.

82. Wenhua Wang, Xin Liu, Zhibao Zhang, Yin M, Xiang Chen, Shuang Zhao, Lisha Wu. Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. Oxid Med Cell Longev. 2022; 2022:8172866.

83. Yi Xiao, Danrong Jing, Zhenwei Tang, Cong Peng, Yin M, Hong Liu, Xiang Chen, Minxue Shen. Serum lipids and risk of incident psoriasis: a prospective cohort study from the UK Biobank study and Mendelian randomization analysis. J Invest Dermatol, 2022; S0022-202X(22)01667-0.

84. Yangyi Zhang^#, Jianfu Xia^#, Jiye Zhang, Jinlei Mao, Hao Chen, Hui Lin, Pan Jiang, Xinzhong He, Xiaodong Xu,Yin M*, Zhifei Wang. Validity of a Soft and Flexible 3D-Printed Nissen Fundoplication Model in Surgical Training. International Journal of Bioprinting,2022; 8 (2).

85. Xin Li^#, Shuang Zhao^#, Xiaohui Bian^#, Lining Zhang, Lixia Lu, Shiyao Pei, Liang Dong, Wensheng Shi, Lingjuan Huang, Xiyuan Zhang, Mingliang Chen, Xiang Chen*,Yin M*. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics, 2022; 12(17): 7532-7549.